Publications

 find all of our publications on PubMed

 

 

  1. DDR2 confers ferroptosis resistance to cancer-associated fibroblasts and attenuates PARPi sensitivity of ovarian tumor cells. Lesage, J., DiMauro, A., Schab, A., Stidham, S., Mullen, M., Fuh, K., & Longmore, G. (2025). Molecular cancer research : MCR, 10.1158/1541-7786.MCR-25-0268. https://doi.org/10.1158/1541-7786.MCR-25-0268
  2. Multi-omic Characterization of Pre- and Post-neoadjuvant Chemotherapy Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.  Valentine, M., Mullen, M., Kotnik, E., Powell, M., Thaker, P., McCourt, C., Kuroki, L., Hagemann, A., Arend, R., Holehouse, A., Mitra, R., Mutch, D., & Fuh, K. (2025). Cancer research, 10.1158/0008-5472.CAN-24-3804. https://doi.org/10.1158/0008-5472.CAN-24-3804
  3. Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity. Liu, T., Zhang, M., Farsh, T., Li, H., Kishishita, A., Barpanda, A., Leung, S., Zhu, J., Jung, H., Hua, J. T., Zhu, X., Kim, A., Goo, Y., Son, M., Kim, J., Subramanian, A., Sjöström, M., Fuh, K., Chapman, J., Carnevale, J., … DeSelm, C. (2025).  Nature communications, 16(1), 5616. https://doi.org/10.1038/s41467-025-60745-x
  4. Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. Schab, A., Compadre, A., Drexler, R., Loeb, M., Rodriguez, K.,  …  , Fuh, K., ....  Mullen, M. M. (2025). The Journal of clinical investigation, 135(13), e189511. https://doi.org/10.1172/JCI189511
  5. APOBEC3A drives ovarian cancer metastasis by altering epithelial-mesenchymal transition. Devenport, J. M., Tran, T., Harris, B. R., Fingerman, D., DeWeerd, R. A., Elkhidir, L. H., LaVigne, D., Fuh, K., Sun, L., Bednarski, J. J., Drapkin, R., Mullen, M. M., & Green, A. M. (2025). JCI insight, 10(5), e186409. https://doi.org/10.1172/jci.insight.186409
  6. Fragmented Care and Guideline-Concordant Treatment in Locally Advanced Cervical Cancer. Mvemba, A., Liang, J., Swanson, M., Yoshida, E., Ueda, S., Fuh, K., Chen, L. M., & Cham, S. (2025). Obstetrics and gynecology, 145(4), 387–394. https://doi.org/10.1097/AOG.0000000000005869
  7. APOBEC3A drives ovarian cancer metastasis by altering epithelial-mesenchymal transition. Devenport, J. M., Tran, T., Harris, B. R., Fingerman, D., DeWeerd, R. A., Elkhidir, L. H., LaVigne, D., Fuh, K., Sun, L., Bednarski, J. J., Drapkin, R., Mullen, M. M., & Green, A. M. (2025). JCI insight, 10(5), e186409. https://doi.org/10.1172/jci.insight.186409
  8. Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology. Liang, J., Mvemba, A., Swanson, M., Hsu, I. J., Alvarez, E., Chapman, J., Fuh, K., Chen, L. M., & Cham, S. (2025). American journal of obstetrics and gynecology, S0002-9378(25)00113-9. Advance online publication.

 

  1. Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice.  Zhou, Q., Harding, J. C., Fan, P., Spasojevic, I., Kovacs, A., Akk, A., Mitchell, A., Springer, L. E., Gaut, J. P., Rauch, D. A., Wickline, S. A., Pham, C. T. N., Fuh, K., & Pan, H. (2024). Nanomaterials (Basel, Switzerland), 14(21), 1752.
  2. Tumour evolution and microenvironment interactions in 2D and 3D space.  Mo, C. K., Liu, J., Chen, S., Storrs, E., Targino da Costa, A. L. N., Houston, A., Wendl, M. C., Jayasinghe, R. G., Iglesia, M. D., Ma, C., Herndon, J. M., Southard-Smith, A. N., Liu, X., Mudd, J., Karpova, A., Shinkle, A., Goedegebuure, S. P., Abdelzaher, A. T. M. A., Bo, P., Fulghum, L., … Fuh, K., ... Ding, L. (2024). Nature, 634(8036), 1178–1186. https://doi.org/10.1038/s41586-024-08087-4
  3. A toolkit for a modern gynecologic oncology tissue bank. Gynecologic oncology.​​​ Graham, O., Rodriguez, J., Abbott, R., Lomonosova, E., Fashemi, B., Drexler, R., Grither, W., Rodriguez, K., Compadre, A., Loeb, M., Sanders, B., Kuroki, L., Hagemann, A. R., McCourt, C., Thaker, P. H., Fuh, K., Powell, M. A., Hagemann, I. S., Mutch, D. G., Khabele, D., … Mullen, M. M. (2024). Gynecologic oncology, 189, 1–8. Advance online publication. https://doi.org/10.1016/j.ygyno.2024.07.001
  4. A RAD18-UBC13-PALB2-RNF168 axis mediates replication fork recovery in BRCA1-deficient cancer cells. Nucleic acids research, gkae563. Cybulla, E., Wallace, S., Meroni, A., Jackson, J., Agashe, S., Tennakoon, M., Limbu, M., Quinet, A., Lomonosova, E., Noia, H., Tirman, S., Wood, M., Lemacon, D., Fuh, K., Zou, L., & Vindigni, A. (2024). Advance online publication. https://doi.org/10.1093/nar/gkae563
  5. Updates in the Use of Targeted Therapies for Gynecologic Cancers. Cantillo, E., Blanc-Durand, F., Leary, A., Slomovitz, B. M., Fuh, K., & Washington, C. (2024). American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44(3), e438582. https://doi.org/10.1200/EDBK_438582
  6. Endometrial cancer at recurrence: To re-sequence or not to re-sequence. Fuh, K., & Manning-Geist, B. L. (2024). Gynecologic oncology reports, 53, 101414. https://doi.org/10.1016/j.gore.2024.101414
  7. ROR2/Wnt5a Signaling Regulates Directional Cell Migration and Early Tumor Cell Invasion in Ovarian Cancer. Grither, W. R., Baker, B., Morikis, V. A., Ilagan, M. X. G., Fuh, K. C., & Longmore, G. D. (2024).  Molecular cancer research : MCR, 22(5), 495–507. https://doi.org/10.1158/1541-7786.MCR-23-0616
  8. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Akinjiyan, F. A., Ibitoye, Z., Zhao, P., Shriver, L. P., Patti, G. J., Longmore, G. D., & Fuh, K. C. (2024). Oncogene, 43(3), 189–201. https://doi.org/10.1038/s41388-023-02884-3

 

  1. Epigenetic regulation during cancer transitions across 11 tumour types. Terekhanova, N. V., Karpova, A., Liang, W. W., Strzalkowski, A., Chen, S., Li, Y., Southard-Smith, A. N., Iglesia, M. D., Wendl, M. C., Jayasinghe, R. G., Liu, J., Song, Y., Cao, S., Houston, A., Liu, X., Wyczalkowski, M. A., Lu, R. J., Caravan, W., Shinkle, A., Naser Al Deen, N., … Fuh, K. C., ... Ding, L. (2023).  Nature, 623(7986), 432–441. https://doi.org/10.1038/s41586-023-06682-5
  2. Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins. Schab, A. M., Greenwade, M. M., Stock, E., Lomonosova, E., Cho, K., Grither, W. R., Noia, H., Wilke, D., Mullen, M. M., Hagemann, A. R., Hagemann, I. S., Thaker, P. H., Kuroki, L. M., McCourt, C. K., Khabele, D., Powell, M. A., Mutch, D. G., Zhao, P., Shriver, L. P., Patti, G. J., … Fuh, K. C. (2023). Molecular cancer research : MCR, 21(11), 1234–1248. https://doi.org/10.1158/1541-7786.MCR-23-0347
  3. Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. Kotnik, E. N., Mullen, M. M., Spies, N. C., Li, T., Inkman, M., Zhang, J., Martins-Rodrigues, F., Hagemann, I. S., McCourt, C. K., Thaker, P. H., Hagemann, A. R., Powell, M. A., Mutch, D. G., Khabele, D., Longmore, G. D., Mardis, E. R., Maher, C. A., Miller, C. A., & Fuh, K. C. (2023). Communications biology, 6(1), 688. https://doi.org/10.1038/s42003-023-05026-3
  4. Reproductive Scientist Development Program: Bridging the Gap to the Physician Scientist Career. Lo, J. O., Boniface, E. R., Heflin, A., Stanic-Kostic, A. K., Fuh, K. C., & Schust, D. J. (2023). Reproductive sciences (Thousand Oaks, Calif.), 30(9), 2615–2622. https://doi.org/10.1007/s43032-023-01234-8
  5. Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays. van Biljon, L., Fashemi, B., Rodriguez, J., Graham, O., Compadre, A., Fuh, K., Khabele, D., & Mullen, M. (2023). Journal of visualized experiments : JoVE, (192), 10.3791/64881. https://doi.org/10.3791/64881
  6. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. Graham, O., Rodriguez, J., van Biljon, L., Fashemi, B., Graham, E., Fuh, K., Khabele, D., & Mullen, M. (2023). Journal of visualized experiments : JoVE, (191), 10.3791/64878. https://doi.org/10.3791/64878